# 1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)

> **NCT02283190** · PHASE1 · COMPLETED · sponsor: **Ashkan Emadi** · enrollment: 5 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Erwinase

## Key facts

- **NCT ID:** NCT02283190
- **Lead sponsor:** Ashkan Emadi
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-12
- **Final completion:** 2017-09
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2018-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02283190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02283190, "1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02283190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*